FLT3-Asp835 mutations lead to constitutive activation of FLT3 (36) and have been reported in 7–14% of AML (3), 3% of myelodysplastic syndromes, and 3% of acute lymphoblastic leukemia cases (37). Here, FLT3 is linked to myelodysplastic syndrome.